Meet Adaeze Nwosu Iheme, M.D.
Adaeze Nwosu Iheme, M.D.
Department of General Oncology, Division of Cancer Medicine
About Dr. Adaeze Nwosu Iheme
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor (Joint appointment), Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
2013 | St. George's University School of Medicine, West Indies, GD, MD |
2008 | IMO State University, IMO, NG, MD |
Postgraduate Training
2016-2019 | Clinical Fellowship, Hematology/Oncology, University of Florida, Gainesville, Florida |
2013-2016 | Clinical Residency, Internal Medicine, Newark Beth Israel Medical Center, Newark, New Jersey |
Board Certifications
2019 | American Board of Internal Medicine-Hematology |
2019 | American Board of Internal Medicine-Oncology |
2016 | American Board of Internal Medicine |
Experience & Service
Other Appointments/Responsibilities
Consultant, Victoria Hematology-Oncology Associates, Victoria, TX, 2019 - Present
Honors & Awards
2018 | ASCO Educational Book Expert Panel, ASCO |
2017 | ASCO Educational Book Expert Panel, ASCO |
2017 | Travel Award, Florida Association of Clinical Oncology |
2016 | RWJ Barnabas Health Chief Resident, Beth Israel Medical Center |
2016 | Top Resident Representative, Resident Cultural Forum |
2015 | Top Resident Representative, Resident Cultural Forum |
2015 | American College of Physician's Young Achiever's Award, American College of Physicians |
2015 | RWJ Barnabas Health Chief Resident, Beth Israel Medical Center |
2008 | Gold Stethoscope Award, WIMS Nigeria |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Skelton WP, Dibenedetto SW, Pang SS, Pan K, Barish JL, Nwosu-Iheme A, Dang L. A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer. Cureus 12(1):e6806, 2020. e-Pub 2020. PMID: 32140364.
- Nwosu-Iheme A, Ghanem S, Patel A, Zhuang Y, Seifert R, Murthy H. A Rare Presentation of Hemophagocytic Lymphohistiocytosis in a Patient with Untreated Chronic Lymphocytic Leukemia: A case report and review of the literature. Herbert Open Access Journals 6(2):1-5, 2018. PMID: None.
- Patel A, Ghanem S, Nwosu-Iheme A, Fletcher B. Idiopathic Pulmonary Vein Thrombosis – A presentation of two case reports and review of the current literature. Symbiosis online publishing 2:1-6, 2017. PMID: None.
- Vijaykumar, Baran D, Nwosu-Iheme A. Successful Use of Extracorporeal Membrane Oxygenation for Silicone Embolism Syndrome and Pulmonary Hemorrhage. Chest Journal, 2016. e-Pub 2016. PMID: None.
- Orsini J, Nwosu-Iheme A, Medavaram S, Cohen AJ. Pituitary Metastasis from Breast Cancer Presenting as SIADH. Journal Of Endocrinology & Metabolism 5(4):256-260, 2015. PMID: None.
- Shah S, Nwosu-Iheme A, Cohen AJ. Impact of Hydroxyurea on Sickle Cell Patients Managed in a Community Medical Center. Ash Publications 126(23):3411, 2015. PMID: None.
Editorials
- Nwosu-Iheme A, Unnikrishnan A. Selecting Patients for CDK4/6 inhibitors in Metastatic Breast Cancer. ASCO Daily Post. PMID: None.
Abstracts
- Valero V, Mouabbi J, Alonzo H, Nwosu-Iheme A, Murthy R, Huang X, Qiao W, Patel M, Pohlmann PR, Rauch G, Checka C, Hunt K, Tripathy D, Meric-Bernstam F, Symmans F. 132P Neoadjuvant zanidatamab for stage I node-negative HER2- positive breast cancer (BC). ESMO Open 8(1), 2023. PMID: None.
- Patel A, Forat Lufti AA, Adaeze N, Markham MJ. An Interactive Multimodality Curriculum Teaching Medicine Residents about Oncologic Documentation and Billing. The Journal of Teaching and Learning Resources 8265, 2018. PMID: None.
- Adaeze N, Cohen AJ. 3411 Impact of Hydroxyurea on Sickle Cell Patients in a Community Hospital. American Society of Hematology 126(23), 2015. PMID: None.
Patient Reviews
CV information above last modified July 17, 2024